Journal article icon

Journal article

The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells

Abstract:

The incidence of treatment-related neuroendocrine (NE) prostate cancer (t-NEPC) is rising as more potent drugs targeting the androgen signaling axis are clinically implemented. Neuroendocrine transdifferentiation (NEtD), an putative initial step in t-NEPC development, is induced by androgen deprivation therapy (ADT) or anti-androgens, and by activation of the β2-adrenergic receptor (ADRB2) in prostate cancer cell lines. Thus, understanding whether ADRB2 is involved in ADT-initiated NEtD may a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1158/1541-7786.mcr-18-0605

Authors


More by this author
Role:
Author
ORCID:
0000-0002-0794-7737
More by this author
Role:
Author
ORCID:
0000-0003-2931-3652
Expand authors...
Publisher:
American Association of Cancer Research Publisher's website
Journal:
Molecular Cancer Research Journal website
Volume:
17
Issue:
11
Pages:
2154-2168
Publication date:
2019-08-08
Acceptance date:
2019-07-10
DOI:
EISSN:
1557-3125
ISSN:
1541-7786
Pmid:
31395667
Source identifiers:
1041741
Language:
English
Keywords:
Pubs id:
pubs:1041741
UUID:
uuid:f1d0a133-6c4f-4757-b6f7-8c140b68f3f2
Local pid:
pubs:1041741
Deposit date:
2019-08-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP